Search
Telbivudine
go.drugbank.com/drugs/DB01265ApprovedWithdrawnTelbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.
Synonyms: L-DTProducts: SEBIVO (600 MG), SEBIVO 600 MG FILM KAPLI TABLET, 28 ADETFilanesib
go.drugbank.com/drugs/DB06040InvestigationalFilanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
TRC093
go.drugbank.com/drugs/DB06356InvestigationalTRC093 is a recombinant humanized IgG1k monoclonal antibody.
ICX-RHY
go.drugbank.com/drugs/DB05716ExperimentalThe drug was under investigation in clinical trials in the UK for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa. … ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.
Ceramide NP
go.drugbank.com/drugs/DB14111InvestigationalCeramide 3 consists of a phytosphingosine backbone N-acylated with a saturated fatty acid (stearic acid) [A27233]. It is widely used as a moisturizer in various cosmetic and personal products. … Ceramide NP is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin.
Synonyms: Cer(t18:0/18:1n-9), N-oleoylphytosphingosineMivebresib
go.drugbank.com/drugs/DB21300InvestigationalThe usage of the INN stem '-bresib' in the name indicates that Mivebresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic. … Mivebresib is under investigation in clinical trial NCT04480086 (Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants
PF-03187207
go.drugbank.com/drugs/DB05746InvestigationalBased on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.
Siagoside
go.drugbank.com/drugs/DB12351InvestigationalIt is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and repair. … Treatment results in a 52% decrease in mortality 48 hours after the induction of ischemia in gerbils by permanent unilateral ligation of the common carotid artery.
GTX-758
go.drugbank.com/drugs/DB14969InvestigationalGTX-758 is under investigation in clinical trial NCT01420861 (GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer).